Evidence map›Paper›PMID 28500562›Full record

ArticleJournal of neuro-oncology2017

Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.

Andrea O Fontana, Deborah Piffaretti, Francesco Marchi, Floriana Burgio, Ana Bela Faia-Torres, Paolo Paganetti, Sandra Pinton, Uwe Pieles, Michael Reinert

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. In Vivo Evaluation ofPharmaceutics · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Andrea O FontanaLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Deborah PiffarettiLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Francesco MarchiLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Floriana BurgioLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Ana Bela Faia-TorresFHNW, Muttenz, BL, Switzerland.
Paolo PaganettiLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Sandra PintonLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland.
Uwe PielesFHNW, Muttenz, BL, Switzerland.
Michael ReinertLaboratories of Biomedical Neurosciences (LBN), Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ticino, Switzerland. michael.reinert@eoc.ch.ORCID http://orcid.org/0000-0002-0971-9543
Laboratory for Biomedical Neurosciences · CHFHNW University of Applied Sciences and Arts · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extent of 5-aminolevulinic acid (5-ALA) guided tumor resection has a determining impact in high-grade glioma and glioblastoma surgery. Yet the intensity of the 5-ALA induced fluorescence may vary within the tumor. We aimed to correlate 5-ALA induced fluorescence with the expression of epithelial growth factor receptor (EGFR) and its constitutively active version EGFRvIII in different glioblastoma (GBM) cell lines. To elucidate the role of EGFR in the metabolism of 5-ALA in GBM cell lines with variable EGFR expression status, we analyzed the activation of EGFR by its primary ligand EGF, and its downstream effect on Heme oxygenase-1 (HO-1), a key enzyme regulating the metabolism of Protoporphyrin IX (PpIX), the fluorescent metabolite of 5-ALA. Effects of direct pharmacological inhibition by Tin(IV)-Protoporphyrin (SnPP) or gene knockdown by small interfering RNA (siRNA) on HO-1 enzyme were analyzed in respect to 5-ALA induced fluorescence. Furthermore, inhibition of EGFR by Gefitinib was tested. A significant difference in 5-ALA induced fluorescence was obtained in U87MG (low EGFR expression) and LN229EGFR cells (EGFR overexpression) compared to BS153 (EGFR overexpression/EGFRvIII+). Treatment of U87MG and LN229EGFR cells with EGF significantly reduced cellular fluorescence, by promoting HO-1 transcription and expression in a concentration-dependent manner. This effect could be reversed by EGFR-specific siRNA treatment, which reduced protein expression of about 80% in U87MG. Remarkably, inhibition of HO-1 activity by SnPP or reduction of HO-1 protein levels by siHO-1 treatment restored fluorescence in all cell lines, independently of EGFR quantitative and qualitative expression. Gefitinib treatment was able to restore fluorescence after EGF stimulation in U87MG cells but not in BS153 cells, overexpressing EGFR/EGFRvIII. In GBM cell lines, 5-ALA induced fluorescence is variable and influenced by EGF-induced downstream activation of HO-1. HO-1 protein expression was identified as a negative regulator of 5-ALA induced fluorescence in GBM cells. We further propose that co-expression of EGFRvIII but not quantitative EGFR expression influence HO-1 activity and therefore cellular fluorescence.

Indexed as

Aminolevulinic AcidFluorescent DyesAstrocytesCell Line, TumorEpidermal Growth FactorErbB ReceptorsGefitinibGene ExpressionGlioblastomaHeme Oxygenase-1HumansProtein Kinase InhibitorsQuinazolinesRNA, MessengerAminolevulinic AcidEGFR protein, humanEpidermal Growth Factorepidermal growth factor receptor VIIIErbB ReceptorsFluorescent DyesGefitinibHeme Oxygenase-1HMOX1 protein, humanProtein Kinase InhibitorsQuinazolinesRNA, Messenger5-ALAEGFEGFREGFR overexpressionEGFRvIIIGefitinibGlioblastomaHeme Oxygenase-1Tin(IV)-protoporphyrin

Identifiers

PMID28500562
PMCPMC5537329
OpenAlexW2614012589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.